GlobeNewswire Inc.··NaKura Oncology's Darlifarnib-Cabozantinib Combo Shows Promise in Resistant Kidney Cancer
Kura Oncology reports darlifarnib plus cabozantinib achieved 44% response rate in cabozantinib-pretreated renal cell carcinoma patients, potentially overcoming drug resistance.
KURAclinical trial dataobjective response rate